Michele Fornaro1, Brendon Stubbs2. 1. New York Psychiatric Institute, Columbia University, NYC, USA; Department of Education Sciences, University of Catania, Italy. Electronic address: mf3000@columbia.edu. 2. Faculty of Education and Health, University of Greenwich, Southwood Site, Avery Hill Road, Eltham, London SE9 2UG, UK. Electronic address: b.stubbs@greenwich.ac.uk.
Abstract
BACKGROUND: Uncertainty exists regarding the prevalence and moderators of migraine comorbidity among people with bipolar disorder (BD). We conducted a meta-analysis and meta-regression to investigate the prevalence and moderators of migraine among people with BD. METHOD: Two authors independently searched major electronic databases from inception till 02/2015. Articles were included that reported the prevalence of migraine in people with BD with or without a control group. A random effects meta-analysis and exploratory meta-regression were conducted. RESULTS: Fourteen studies were included encompassing 3976 individuals with BD (mean age 35.5 years, SD 7.6, 29% male). The overall pooled prevalence of migraine was 34.8% (95% CI=25.54-44.69). The prevalence of migraine was higher among people with BD-II (54.17%, 95% CI=31.52-75.95, n=742) compared to BD-I (32.7%, 95% CI=18.16-49.19, n=2138, z=3.97, p<0.0001). The prevalence of migraine was 33.9% (95% CI=26.02-42.44), 39.5% (95% CI=18.81-62.39) and 47.11% (95% CI=22.24-72.77) in North America, Europe and South America respectively. The prevalence of migraine was higher when classified according to recognized criteria at 47.91% (95% CI=32.51-63.5) compared to non-recognized criteria (20.0%, 95% CI=12.44-29.06, z=-8.40, p<0.0001). Meta regression suggests mean age may be a potential moderator. CONCLUSION: Migraine is common and burdensome among people with BD. People with BD-II appear to be particularly affected. Nonetheless, future research is required to better understand these relationships, with a special emphasis toward the course specifiers of comorbid migraine cases of either BD-I vs. BD-II.
BACKGROUND: Uncertainty exists regarding the prevalence and moderators of migraine comorbidity among people with bipolar disorder (BD). We conducted a meta-analysis and meta-regression to investigate the prevalence and moderators of migraine among people with BD. METHOD: Two authors independently searched major electronic databases from inception till 02/2015. Articles were included that reported the prevalence of migraine in people with BD with or without a control group. A random effects meta-analysis and exploratory meta-regression were conducted. RESULTS: Fourteen studies were included encompassing 3976 individuals with BD (mean age 35.5 years, SD 7.6, 29% male). The overall pooled prevalence of migraine was 34.8% (95% CI=25.54-44.69). The prevalence of migraine was higher among people with BD-II (54.17%, 95% CI=31.52-75.95, n=742) compared to BD-I (32.7%, 95% CI=18.16-49.19, n=2138, z=3.97, p<0.0001). The prevalence of migraine was 33.9% (95% CI=26.02-42.44), 39.5% (95% CI=18.81-62.39) and 47.11% (95% CI=22.24-72.77) in North America, Europe and South America respectively. The prevalence of migraine was higher when classified according to recognized criteria at 47.91% (95% CI=32.51-63.5) compared to non-recognized criteria (20.0%, 95% CI=12.44-29.06, z=-8.40, p<0.0001). Meta regression suggests mean age may be a potential moderator. CONCLUSION:Migraine is common and burdensome among people with BD. People with BD-II appear to be particularly affected. Nonetheless, future research is required to better understand these relationships, with a special emphasis toward the course specifiers of comorbid migraine cases of either BD-I vs. BD-II.
Authors: Nathan Risch; Jonathan Dubois; Katia M'bailara; Irena Cussac; Bruno Etain; Raoul Belzeaux; Caroline Dubertret; Emmanuel Haffen; Raymund Schwan; Ludovic Samalin; Paul Roux; Mircea Polosan; Marion Leboyer; Philippe Courtet; Emilie Olié Journal: J Clin Med Date: 2022-02-08 Impact factor: 4.241
Authors: M L Prieto; E Ryu; G D Jenkins; A Batzler; M M Nassan; A B Cuellar-Barboza; J Pathak; S L McElroy; M A Frye; J M Biernacka Journal: Transl Psychiatry Date: 2016-08-16 Impact factor: 6.222
Authors: Shahram Bahrami; Guy Hindley; Bendik Slagsvold Winsvold; Kevin S O'Connell; Oleksandr Frei; Alexey Shadrin; Weiqiu Cheng; Francesco Bettella; Linn Rødevand; Ketil J Odegaard; Chun C Fan; Matti J Pirinen; Heidi M Hautakangas; Anders M Dale; Srdjan Djurovic; Olav B Smeland; Ole A Andreassen Journal: Brain Date: 2022-03-29 Impact factor: 13.501